Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 59


Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.

Noeparast A, Teugels E, Giron P, Verschelden G, De Brakeleer S, Decoster L, De Grève J.

Oncotarget. 2016 Aug 26. doi: 10.18632/oncotarget.11635.


Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT).

De Grève J, Van Meerbeeck J, Vansteenkiste JF, Decoster L, Meert AP, Vuylsteke P, Focan C, Canon JL, Humblet Y, Berchem G, Colinet B, Galdermans D, Bosquée L, Vermeij J, Dewaele A, Geers C, Schallier D, Teugels E.

PLoS One. 2016 Mar 31;11(3):e0147599. doi: 10.1371/journal.pone.0147599.


The impact of an interventional counselling procedure in families with a BRCA1/2 gene mutation: efficacy and safety.

Sermijn E, Delesie L, Deschepper E, Pauwels I, Bonduelle M, Teugels E, De Grève J.

Fam Cancer. 2016 Apr;15(2):155-62. doi: 10.1007/s10689-015-9854-4.


Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.

Umelo I, Noeparast A, Chen G, Renard M, Geers C, Vansteenkiste J, Giron P, De Wever O, Teugels E, De Grève J.

Oncotarget. 2016 Jan 19;7(3):3068-83. doi: 10.18632/oncotarget.6585.


Combined inhibition of rho-associated protein kinase and EGFR suppresses the invasive phenotype in EGFR-dependent lung cancer cells.

Umelo IA, Wever OD, Kronenberger P, Noor A, Teugels E, Chen G, Bracke M, Grève JD.

Lung Cancer. 2015 Nov;90(2):167-74. doi: 10.1016/j.lungcan.2015.08.008.


Frequent incidence of BARD1-truncating mutations in germline DNA from triple-negative breast cancer patients.

De Brakeleer S, De Grève J, Desmedt C, Joris S, Sotiriou C, Piccart M, Pauwels I, Teugels E.

Clin Genet. 2016 Mar;89(3):336-40. doi: 10.1111/cge.12620.


Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade.

Umelo IA, De Wever O, Kronenberger P, Van Deun J, Noor A, Singh K, Teugels E, Chen G, Bracke M, De Grève J.

Oncotarget. 2015 Aug 21;6(24):20132-44.


Detection of EGFR-TK domain-activating mutations in NSCLC with generic PCR-based methods.

Shahi RB, De Brakeleer S, De Grève J, Geers C, In't Veld P, Teugels E.

Appl Immunohistochem Mol Morphol. 2015 Mar;23(3):163-71. doi: 10.1097/PDM.0000000000000035.


Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.

De Grève J, Moran T, Graas MP, Galdermans D, Vuylsteke P, Canon JL, Schallier D, Decoster L, Teugels E, Massey D, Chand VK, Vansteenkiste J.

Lung Cancer. 2015 Apr;88(1):63-9. doi: 10.1016/j.lungcan.2015.01.013.


Mixed adenoneuroendocrine carcinoma of the colon: molecular pathogenesis and treatment.

Vanacker L, Smeets D, Hoorens A, Teugels E, Algaba R, Dehou MF, De Becker A, Lambrechts D, De Greve J.

Anticancer Res. 2014 Oct;34(10):5517-21.


Detection of EGFR-TK Domain-activating Mutations in NSCLC With Generic PCR-based Methods.

Shahi RB, De Brakeleer S, De Grève J, Geers C, In't Veld P, Teugels E.

Diagn Mol Pathol. 2014 Jan 30.


miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells.

Chen G, Umelo IA, Lv S, Teugels E, Fostier K, Kronenberger P, Dewaele A, Sadones J, Geers C, De Grève J.

PLoS One. 2013;8(3):e60317. doi: 10.1371/journal.pone.0060317.


Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib.

Chen G, Noor A, Kronenberger P, Teugels E, Umelo IA, De Grève J.

PLoS One. 2013;8(3):e59708. doi: 10.1371/journal.pone.0059708.


Systematic detection of pathogenic alu element insertions in NGS-based diagnostic screens: the BRCA1/BRCA2 example.

De Brakeleer S, De Grève J, Lissens W, Teugels E.

Hum Mutat. 2013 May;34(5):785-91. doi: 10.1002/humu.22297.


Geographical distribution of Slovenian BRCA1/2 families according to family origin: implications for genetic screening.

Krajc M, Zadnik V, Novaković S, Stegel V, Teugels E, Bešič N, Hočevar M, Vakselj A, De Grève J, Zgajnar J.

Clin Genet. 2014 Jan;85(1):59-63. doi: 10.1111/cge.12119.


Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents.

Chen G, Kronenberger P, Teugels E, Umelo IA, De Grève J.

Biochem Biophys Res Commun. 2013 Feb 15;431(3):623-9. doi: 10.1016/j.bbrc.2012.12.070.


Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab.

Lv S, Teugels E, Sadones J, De Brakeleer S, Duerinck J, Du Four S, Michotte A, De Grève J, Neyns B.

Int J Oncol. 2012 Sep;41(3):1029-35. doi: 10.3892/ijo.2012.1539.


Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.

De Grève J, Teugels E, Geers C, Decoster L, Galdermans D, De Mey J, Everaert H, Umelo I, In't Veld P, Schallier D.

Lung Cancer. 2012 Apr;76(1):123-7. doi: 10.1016/j.lungcan.2012.01.008.


Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma.

Lv S, Teugels E, Sadones J, Quartier E, Huylebrouck M, DU Four S, LE Mercier M, DE Witte O, Salmon I, Michotte A, DE Grève J, Neyns B.

Anticancer Res. 2011 Dec;31(12):4457-63.

Items per page

Supplemental Content

Loading ...
Support Center